Want to see TECX full AI Analyst Report?
TECX Stock Chart & Stats
$30.37
-$1.24(-3.92%)
At close: 4:00 PM EDT
$30.37
-$1.24(-3.92%)
Day’s Range― - ―
52-Week Range$14.39 - $39.53
Previous Close$30.37
Volume99.11K
Average Volume (3M)178.91K
Market Cap
$528.90M
Enterprise Value$137.35
Total Cash (Recent Filing)$227.07M
Total Debt (Recent Filing)$4.40M
Price to Earnings (P/E)―
Beta1.28
Next Earnings
Nov 05, 2026EPS Estimate
-1.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.57
Shares Outstanding18,869,186
10 Day Avg. Volume173,306
30 Day Avg. Volume178,909
Financial Highlights & Ratios
PEG Ratio-1.69
Price to Book (P/B)1.52
Price to Sales (P/S)0.00
P/FCF Ratio-6.34
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$79.75Price Target Upside162.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-5.33
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very Low Leverage / Strong Balance SheetA very low debt-to-equity base provides durable financial flexibility to fund multi-year clinical programs, reduces insolvency risk, and preserves optionality for strategic partnerships or opportunistic acquisitions without immediate refinancing pressure.
Completed Enrollment In Global Phase 2 APEX (TX45)Completion of a pivotal-size Phase 2 trial is a structural milestone that de-risks development timing, creates a defined binary catalyst (topline data), and materially improves the company's ability to pursue partnerships, licensing, or late-stage funding if results are positive.
Improved Equity Base From Prior FundraisingAn improved equity base reflects management's ability to access capital and restore the balance sheet, supporting ongoing R&D spending and reducing short-term dilution pressure versus peers that face weaker capitalization.
Bears Say
No Revenue; Growing Net LossesBeing pre-revenue with widening net losses means the business depends entirely on future clinical success or external financing; this structural cash dependency increases dilution and execution risk over the next several quarters absent positive trial outcomes.
Accelerating Negative Operating Cash FlowA rapidly increasing operating cash burn consumes runway and forces recurrent financing or partnership needs; persistent negative cash flow limits strategic flexibility and can pressure R&D timelines if capital access weakens.
Pre-revenue, Rising Operating Spend & Limited VisibilityHigh and rising operating spend without commercial revenue makes future performance binary and driven by trial outcomes; this structural uncertainty reduces predictability of returns and increases the probability of future dilutive financings.
Tectonic Therapeutic News
TECX FAQ
What was Tectonic Therapeutic Inc’s price range in the past 12 months?
Tectonic Therapeutic Inc lowest stock price was $14.38 and its highest was $39.53 in the past 12 months.
What is Tectonic Therapeutic Inc’s market cap?
Tectonic Therapeutic Inc’s market cap is $528.90M.
When is Tectonic Therapeutic Inc’s upcoming earnings report date?
Tectonic Therapeutic Inc’s upcoming earnings report date is Nov 05, 2026 which is in 88 days.
How were Tectonic Therapeutic Inc’s earnings last quarter?
Tectonic Therapeutic Inc released its earnings results on Aug 06, 2026. The company reported -$1.18 earnings per share for the quarter, beating the consensus estimate of -$1.349 by $0.169.
Is Tectonic Therapeutic Inc overvalued?
According to Wall Street analysts Tectonic Therapeutic Inc’s price is currently Undervalued.
Does Tectonic Therapeutic Inc pay dividends?
Tectonic Therapeutic Inc does not currently pay dividends.
What is Tectonic Therapeutic Inc’s EPS estimate?
Tectonic Therapeutic Inc’s EPS estimate is -1.34.
How many shares outstanding does Tectonic Therapeutic Inc have?
Tectonic Therapeutic Inc has 18,869,186 shares outstanding.
What happened to Tectonic Therapeutic Inc’s price movement after its last earnings report?
Tectonic Therapeutic Inc reported an EPS of -$1.18 in its last earnings report, beating expectations of -$1.349. Following the earnings report the stock price went up 2.515%.
Which hedge fund is a major shareholder of Tectonic Therapeutic Inc?
Currently, no hedge funds are holding shares in TECX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tectonic Therapeutic Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$79.75 (162.59% Upside)
$79.75 (162.59% Upside)
Blogger Sentiment
Bullish
TECX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 395.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
37.14%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-19.73%
Trailing 12-Months
Company Description
Tectonic Therapeutic Inc
Tectonic Therapeutic, Inc. operates as a clinical-stage biotechnology firm dedicated to the identification and progression of biologic therapies, primarily therapeutic proteins and antibodies, that regulate the function of G-protein coupled receptors (GPCRs). The company leverages its proprietary GEODe technology platform to facilitate the discovery and development of these GPCR-targeted medicines. Its robust pipeline includes an RXFP1 agonist, currently undergoing Phase 1a and 1b clinical trials for the treatment of heart failure with preserved ejection fraction. Additional programs encompass a GPCR antagonist addressing hereditary hemorrhagic telangiectasia, a bi-functional GPCR modulator aimed at fibrosis, and various other GPCR modulators. Tectonic Therapeutic, Inc. is situated in Watertown, Massachusetts.
TECX Stock 12 Month Forecast
Average Price Target
$79.75
▲(162.59% Upside)
Technical Analysis
Omeros
―
Abeona Therapeutics
―
Mereo Biopharma Group Plc
―
Foghorn Therapeutics
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
35.62% Insiders
15.02% Mutual Funds
0.32% Other Institutional Investors
42.50% Public Companies and
Individual Investors